Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Indwelling vs Intermittent Catheterization Pilot Study (PEE)

28 aprile 2022 aggiornato da: Ottawa Hospital Research Institute

Hip Fracture Patient and the Use of IndwElling vs IntermittEnt Catheterization Pilot Study

The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization. The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this pilot study trial and proceed towards a multi-center trial.

Panoramica dello studio

Descrizione dettagliata

The primary aim of the proposed pilot feasibility is to determine whether it is feasible to recruit patients with a hip fracture into a prospective study and randomize them to either indwelling or intermittent catheterization.

The study hypothesis is that the investigators would be able to show that this study can be incorporated into clinical practice, with satisfactory rate of patient recruitment and retention. Thus, the investigators would be able to compete this vanguard trial and proceed towards a multi-center trial.

Secondary objectives would be related to safety and patient activity that would be important endpoints for the definitive, large scale trial. These would include the following:

  1. Is short term indwelling catheter use associated with reduced incidence of UTI compared to clean intermittent catheterization in patients with hip fracture.
  2. How does patient experience compare between these two forms of treatment?

Eligible patients will be approached for consent at admission and, if willing to participate, will be randomized into Group A or Group B using a web-based, computer-generated randomization with permuted blocks of varying sizes.

Data Collection will include:

  • Urinary symptoms at admission, pre-fracture
  • Date and time of catheter insertion (indwelling or not)
  • Date and time of surgery
  • Type of anesthesia used
  • Date and time of catheter removal
  • Number of catheterizations performed during hospital stay
  • Type of Antibiotic cover during per-operative period (typically 3 doses provided perioperatively)

A clinical research coordinator (CRC) will oversee study recruitment and assess number of study participants to the total number of patients admitted with a hip fracture which will allow for documentation of ability to recruit into the study. Furthermore, the CRC will prospectively record each patent's journey to assess whether enrolled patients are receiving the treatment they are randomized to. All enrolled patients will be asked to fill in a patient satisfaction score that has been in use already at our institution.

A CRC, blinded to the arm patients were randomized to, will be responsible for recording all outcome measures of interest prospectively in the study's database from the participant's electronic medical records. Validity of data extraction will be tested for a randomly selected 10% of the cohort by a second evaluator (CRC not previously involved in the study).

Data analyses will include:

Descriptive Statistics: Given the feasibility purpose of the vanguard trial, descriptive statistics will be used to summarize demographics and baseline prognostic factors of participants allocated to the two trial arms.

Analysis of Primary Outcome: Our primary endpoint is the rate of enrolment to ensure the ability to undertake a larger multi-centered trial. An average rate of 10 patients/month or greater will be considered as ideal for establishing feasibility. An enrollment of less than 5 patients/month will likely jeopardize the ability to feasibly recruit for the larger trial. Whereas, average monthly enrolment of 5 to 10 patients will require a re-evaluation of our recruitment strategy, intervention specifications, and/or eligibility criteria to improve enrolment.

Analysis of Secondary Outcomes: Given the vanguard nature of this trial, the investigators will not undertake inferential analyses of our secondary outcomes but rather these patients will be carried forward into the larger trial.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

120

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Isabel Horton
  • Numero di telefono: 73032 613-737-8899
  • Email: ihorton@ohri.ca

Backup dei contatti dello studio

Luoghi di studio

    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital
        • Contatto:
          • Isabel S Horton
          • Numero di telefono: 73032 6137378899
          • Email: ihorton@ohri.ca

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

50 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Hip fracture (intertrochanteric, femoral neck, femoral head, sub-trochanteric) confirmed by imaging
  • Age ≥50 years
  • Operative treatment planned
  • Admitted under Orthopaedic Surgery
  • Willing and able to sign consent (substitute decision maker)

Exclusion Criteria:

  • Periprosthetic hip fracture
  • Polytrauma
  • Multiple fractures of the lower limbs
  • Previous lower urinary tract surgery
  • Known (past or current) urogenital cancer (prostate, bladder)
  • Urinary tract infection prior to randomization
  • Indwelling catheter present on admission (chronic or placed at previous acute setting)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Indwelling
Foley catheterization upon admission and removed the morning following surgery.
Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
Sperimentale: Intermittent
Intermittent catheterization when post-void residual volume is greater than 400 mL.

Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR>400 mL, an intermittent catheter will be used. If PVR> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.

It is expected that a small percentage of patients in either group will not have a PVR>400 mL preoperatively.

These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Study Feasibility - Enrollment
Lasso di tempo: One year

Number of participants enrolled and willingness of participants to be randomized Comparing the Number of patients screened compared to the number of patients meeting eligibility criteria.

Tracking crossover between the treatment groups, participant retention, and follow-up rates.

One year
Study Feasibility - Screening
Lasso di tempo: One year
Number of patients screened and number meeting eligibility
One year
Study Feasibility - Retention
Lasso di tempo: One year
Participant retention rate in study
One year
Study Feasibility - Follow-up
Lasso di tempo: One year
Rates of participant follow-up
One year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety-Related Outcomes - Rates of UTI
Lasso di tempo: 30 days
Number of patients who present with a post-operative UTI within 30 days of catheterization
30 days
Safety-Related Outcomes - Rates of POUR
Lasso di tempo: 30 days
Number of patients who present with post-operative POUR within 30 days of catheterization
30 days
patient experience questionnaire
Lasso di tempo: pre-operatively, and post-operative day six or at discharge
the patient experience questionnaire, created by the principal investigator of the study, will be used to assess patients level of urogenital pain and discomfort and satisfaction with catheterization.
pre-operatively, and post-operative day six or at discharge

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: George Grammatopoulos, MD, The Ottawa Hospital
  • Investigatore principale: Steven Papp, MD, The Ottawa Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Anticipato)

1 giugno 2022

Completamento primario (Anticipato)

1 maggio 2023

Completamento dello studio (Anticipato)

1 luglio 2023

Date di iscrizione allo studio

Primo inviato

11 aprile 2022

Primo inviato che soddisfa i criteri di controllo qualità

28 aprile 2022

Primo Inserito (Effettivo)

2 maggio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 maggio 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 aprile 2022

Ultimo verificato

1 aprile 2022

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi